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Background. Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, it represents 5–8% of childhood
malignancies. Aim of the Work. To evaluate the epidemiological characteristics and treatment outcome in two pediatric oncology
centers. Patients and Method. A retrospective analysis was performed on 41 medical records of children with RMS during 6
years period. Results. The median age of patients was 6 years with 80.4% below 10 years. Head and neck was the most common
primary site. Embryonal RMS was the most frequent histopathologic subtype. Stage IV was the most frequent stage. According
to IRS postsurgical grouping classiﬁcation, group 4 was the most frequent group. There was a signiﬁcant relationship between
histopathologic subtypes of tumor and metastasis, primary site of tumor and histopathologic subtype, age, metastasis, IRS
presurgical stage and IRS postsurgical group and outcome. The overall survival rate was 56.9% ± 8.4 and the failure free survival
rate was 68.3% ± 7.6. Conclusion. The epidemiological characteristics of our patients are quite near to the worldwide data, apart
from the higher prevalence of stage IV and group 4 with most of the primary tumor site in the extremities. CWS2002 protocol of
therapy had led to improvement in the curability of the disease.
1.Introduction
Rhabdomyosarcoma (RMS) accounts for approximately
3.5% of the cases of cancer among children aged 0 to 14 years
and 2% of the cases among adolescents and young adults
aged 15 to 19 years [1]; The incidence is 4.5 per million
children and 50% of cases are seen in the ﬁrst decade of life
[2]. Approximately, 65% of cases are diagnosed in children
less than six years of age with remaining cases noted in the
10-to-18-year-oldagegroup.Thereisaslightpredilectionfor
diseaseinmales,withamaletofemaleratioof1.3:1[3].Sev-
eral distinct histologic groups have prognostic signiﬁcance,
including embryonal rhabdomyosarcoma (ERMS), which
occursin55%ofpatients;thebotryoidvariant(5%);alveolar
rhabdomyosarcoma (20%); undiﬀerentiated sarcoma (UDS)
in 20% of patients [4]. Distinctive features appear to cluster
around the site of the primary tumor, the age at diagnosis,
and the histologic subtype. Head and neck RMS are more
common in younger children, with orbital tumors being
characterized by embryonal histology in most of cases.
Extremity tumors are more common in adolescents and are
more likely to have an alveolar histologic subtype. Nearly
80% of genitourinary tract RMS are embryonal in nature
[5]. The most common sites are the head and neck (40%),
followed by genitourinary tract (29%), extremities (14%),
trunk (12%), and other sites in less than 5% of patients [6].
Inpatientswithlocalizeddisease,overall5-yearsurvivalrates
have improved to more than 80% with the combined use
of surgery, radiotherapy, and chemotherapy [7]. However,
in patients with metastatic disease, little progress has been
made in survival rates, with a 5-year event-free survival rate
lessthan30%.Thosepatientswithmetastaticdiseasewithout
other high-risk factors including unfavorable site, more than
3 sites, bone marrow involvement, and age younger than 1
year or older than 10 years, have a better prognosis [8].2 ISRN Oncology
2. Patientsand Methods
Aretrospectiveanalysiswasperformedon41medicalrecords
of children with RMS who were admitted, treated, and fol-
lowed up at the hematology/oncology units of pediatric de-
partments,ZagazigandMansouraUniversitychildrenhospi-
tals during the period from June 2004 to June 2009. Patients
were followed up to September 2010. The followup period
ranged from 5 to 74 months with a mean of 20 months. The
medical records were reviewed for
( i )p e r s o n a ld a t af o re x a m p l e ,n a m e ,a g e ,s e x ,c o n s a n -
guinity, and residence,
(ii) presenting symptoms and signs,
(iii) primary site of the tumor,
(iv) histopathological characters of the tumor,
(v) routine laboratory investigations at presentation and
during treatment, for example, complete blood
count, liver function tests, kidney function tests, se-
rum electrolytes, LDH, and alkaline phosphatase,
(vi) imaging studies, for example, plain X-ray, ultra-
sound, CT, and MRI, on primary site and other com-
mon metastatic sites,
(vii) risk stratiﬁcation for patients treated according to
VAC protocol and those treated according to the
German pediatrics soft tissue study group (CWS)
protocol [9],
(viii) treatment protocols including surgery, radiotherapy,
and chemotherapy,
(ix) patients’ outcome.
3. Results
Our study showed that the median age of our patients was 6
years with 80.4% of patients were below the age of 10 years.
The male to female ratio was 1.15:1. Head and neck was
the most common aﬀected primary site of tumor followed
by extremities, then genitourinary, and lastly the retrop-
eritoneum (Table 1).
The embryonal RMS was the most frequent histopatho-
logic subtype, followed by alveolar (28.6%), and lastly the
botryoid and spindle subtypes in 4.7% for each (Table 2).
Tumor size more than 5cm was present in 65.9% of
patients, 12% of patients had lymph node involvement and
44% of patients had metastasis at time of diagnosis (Table 3).
Stage IV was the most frequent stage of our patients
(43.9%), followed by stage III (29.3%), then stage I (17.1%),
and lastly stage II (9.7%). According to IRS postsurgical
grouping classiﬁcation, group 4 was the most frequent group
(43.9%), followed by group 1 (26.8%), then group 3 (19.5%)
and lastly group 2 (9.8%).
There was a signiﬁcant relationship between histopatho-
logic subtypes of tumor and metastasis, all patients with
alveolar subtype had metastasis at time of diagnosis while
only 31% of embryonal subtype had metastasis.
There was highly signiﬁcant (P<0.001) statistical rela-
tionship between primary site of tumor and histopathologic
Table 1: Demographic characteristics and the primary tumor sites
of patients.
n = 41 %
Age (years)
X ±SD 6.3 ±4.3
Range (1–16)
<10 33 80.4
≥10 8 19.6
Gender
Male 22 53.6
Female 19 46.4
Primary site
Head and neck 15 36.6
Extremities 12 29.2
Genitourinary 8 19.6
Retroperitoneum 6 14.6
Table 2: Histopathological subtypes of tumor.
Histopathology n = 41 %
Embryonal 27 65.9
Alveolar 9 21.9
Botryoid 3 7.3
Spindle cell 2 4.9
Table 3: Tumor size, lymph node involvement and distant metasta-
sis of patients.
n = (41) %
Tumor size (cm)
<5 14 34.1
>5 27 65.9
Lymph node
involvement
−ve 36 87.8
+ve 5 12.2
Distant metastasis
−ve 23 56.1
+ve 18 43.9
subtype. All patients with head and neck RMS and 50%
of both genitourinary and retroperitoneum RMS were of
embryonal subtype while 58.3% of extremities RMS were of
alveolar subtype (Table 4).
There was no signiﬁcant relationship between primary
site of tumor and metastasis (Table 4).
There was no signiﬁcant statistical relationship between
primary site of tumor and age (P = 0.4).
The relations between outcome and each of age, sex,
primary site, histopathology, metastasis, IRS postsurgical
grouping,IRSpresurgicalstaging,protocoloftreatment,and
radiotherapy are shown in Tables 5 and 6.ISRN Oncology 3
Table 4: Relationship between primary site of tumor, histopathology, and metastasis.
Head and neck Extremities Genitourinary Retroperitoneum
x
2 P value
n = 15 % n = 12 % n = 8%n = 6%
Histopathology
Embryonal (n = 27) 15 100 5 41.7 4 50.0 3 50.0 26.59 <0.001∗∗
Alveolar (n = 9) 0 0 7 58.3 0 0 2 33.3 21.37 <0.001∗∗
Others (n = 5) 0 0 0 0 4 50.0 1 16.7 14.32 0.002∗
Metastasis
−ve 10 62.5 5 28.6 4 75 4 50 2.09 0.55
+ve 5 37.5 7 71.4 2 25 4 50
∗∗: highly signiﬁcant; ∗: signiﬁcant.
Table 5: Relation between outcome and age, sex, primary site, histopathology, and metastasis.
Survivors Dead
x
2 P value
n = 25 % n = 16 %
Age (years)
< 10 n = 33 23 69.7 10 30.3 5.27 0.02∗
≥10 n = 82 2 5 6 7 5
Gender
Male n = 22 12 54.5 10 45.5 0.83 0.36
Female n = 19 13 68.4 6 31.6
Primary site
Head and neck n = 15 7 46.7 8 53.3 2.57 0.1
Extremities n = 12 8 66.7 4 33.3 0.02 0.88
Genitourinary n = 8 6 75.0 2 25 0.58 0.44
Retroperitoneum n = 6 4 66.7 2 33.3 0.09 0.76
Histopathology
Embryonal n = 27 15 55.6 12 44.4 0.98 0.32
Alveolar n = 9 5 55.6 4 44.4 0.14 0.72
Others n = 5 5 100 0 0 2.02 0.15
Metastasis
−ve n = 23 19 82.6 4 17.4 10.3 0.0013∗
+ve n = 18 6 33.3 12 66.7
∗: signiﬁcant.
There was a signiﬁcant relationship between age and
outcome of patients (P = 0.02). Seventy ﬁve percent of pa-
tients more than 10 years died while about 70% of patients
less than 10 years survived (Table 5).
There was a signiﬁcant relationship between metastasis
andoutcome(P = 0.0013),where66.7%ofpatientswhohad
metastasis at time of diagnosis died while 82.6% of patients
without metastasis survived (Table 5).
TherewasasigniﬁcantrelationshipbetweenIRSpostsur-
gical group and outcome, as 81.8% of group 1 and 100% of
group 2 survived while 61.1% of group 4 died (Table 6).
There was a signiﬁcant relationship between IRS presur-
gicalstageandoutcome,as100%ofstageIsurvivewhile80%
of stage IV died (Table 6).
There was a signiﬁcant relationship between outcome
and protocol of treatment and radiotherapy. Patients who
treated with CWS protocol had a signiﬁcantly better prog-
nosis (P = 0.03) while patients who received radiotherapy
had a signiﬁcantly worse prognosis (P = 0.02) (Table 6).
Theestimatedoverallsurvival(OS)ratewas56.9% ± 8.4
with mean OS time of 47.8 months ±5( Figure 1) and the
estimated failure free survival (FFS) rate was 68.3% ± 7.6
with mean FFS time of 53.3 months ±4.9 (Figure 2).
The estimated OS rate was 66.3% ± 8.9 and 25% ± 15.3
for patients < 10 years and ≥ 10 years old, respectively, while
meanOStimewas53.4months ±5.4and19months ±3.6for
patients<10yearsand≥10yearsold,respectively(Figure 3).4 ISRN Oncology
Table 6: Relationship between outcome and IRS postsurgical groups, IRS presurgical stages, protocol of treatment, and radiotherapy.
Survivors Dead
x
2 P value
n = 25 % n = 16 %
IRS postsurgical group
1 n = 11 9 81.8 2 18.2 1.68 0.19
2 n = 4 4 100 0 0 1.31 0.25
3 n = 8 5 62.5 3 37.5 0.02 0.88
4 n = 18 7 38.9 11 61.1 7.32 0.0072∗
IRS presurgical stage
I n = 7 7 100 0 0 5.27 0.02∗
II n = 4 2 50 2 50 0.22 0.63
III n = 12 9 75 3 25 1.09 0.29
IV n = 18 7 38.9 11 61.1 7.22 0.0012∗
Protocol of treatment
VAC n = 28 14 50 14 50 4.47 0.03∗
CWS n = 13 11 84.6 2 15.4
Radiotherapy
Yes n = 26 12 46.2 14 53.8 6.56 0.01∗
No n = 15 13 86.7 2 13.3
∗: signiﬁcant.
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Figure 1: Overall survival (OS) of patients. The estimated OS rate
was 56.9% ± 8.4 with mean OS time of 47.8 months ±5.
The estimated OS rate was 53.9% ± 10.6 and 41.7% ±
17.3 for patients with embryonal and alveolar rhabdomyo-
sarcoma, respectively (Figure 4).
TheestimatedOSratewas75% ± 21,80.2% ± 12.8,and
22.2% ± 10.8 for patients with stage II, stage III, and stage
IV, respectively (Figure 5).
The estimated OS rate was 48.9% ± 9.6 and 76.9% ±
15.3 for patients on VAC and CWS protocol, respec-
tively. While mean OS time was 42.6 months ±5.9 and
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Figure 2: Failure-free survival (FFS) of patients. The estimated FFS
rate was 68.3% ± 7.6 with mean FFS time of 53.3 months ±4.9.
22 months ±1.7 for patients on VAC and CWS protocol,
respectively (Figure 6).
4. Discussion
Rhabdomyosarcoma (RMS) is a highly malignant childhood
cancer. It is the most common form of soft tissue sarcoma
in the ﬁrst two decades of life, with a peak incidence in
very young children [1]. The median age of our patientsISRN Oncology 5
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Figure 3: OS according to age of patients. The estimated OS rate
was 66.3% ± 8.9 and 25% ± 15.3 for patients < 10 years and ≥ 10
years old respectively, while mean OS time was 53.4 months ±5.4
and 19 months ±3.6 for patients < 10 years and ≥ 10 years old
respectively.
was 6 years with 80.4% of patients were below the age of
10 years. These results are similar to another Egyptian study
conducted by Shouman et al. [10] who reported the same
median age but with 60% of patients below the age of 10
years. The IRS IV reported that the median age of patients
was 5-year, with 72% of patients below the age of 10 years
[11].
In our study, 53.6% of patients were males while 46.4%
were females with male to female ratio of 1.15:1. IRS IV
reported higher male to female ratio (1.6:1) [11].
In our study, head and neck was the most common
aﬀected primary site of tumor (36.6%), followed by extremi-
ties (29%), then genitourinary (19.6%), and lastly retroperi-
toneum in (14.6%). These results are diﬀerent from Abd El-
Aal et al. who reported that the genitourinary is the second
most common aﬀected site (23.6%), after head and neck
(36.4), followed by extremities (16.3), then retroperitoneum
(12.7) [12]. Also the IRS IV found that head and neck was
the most common aﬀected primary site of tumor (41%),
followed by the genitourinary site (31%), then extremities
(13%), and retroperitoneum (7%) [11]. This diﬀerence can
be explained by small number of our patients compared to
these studies.
In our study, embryonal RMS was the most frequent
histopathologic subtype (61.9%) while alveolar RMS rep-
resents 28.6% of patients. Hessissen et al. [13] found that
embryonal subtype represents 73% while alveolar subtype
represents 13% of patients and Abd El-Aal et al. [12]f o u n d
that embryonal and alveolar subtypes represent 87.3% and
12.7% of patients, respectively. The IRS IV reported that the
embryonal subtype represent 70% including the botryoid
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Figure 4: OS according to histopathologic subtypes of tumor. The
estimated OS rate was 53.9% ± 10.6 and 41.7% ± 17.3 for patients
with embryonal and alveolar rhabdomyosarcoma, respectively.
and spindle cellvariants, this is quite near to our results if the
botryoid and spindle cell variants were added to embryonal
subtype (71.7%) [11].
In our study, 65.9% of patients had tumor size more than
5cm at time of diagnosis while 34.1% had tumor size below
5cm. These results are lower than the 75% reported by a
Japanese study conducted by Hosoi et al. [14], and higher
than the 51% and 55% reported by the IRS IV and Abd El-
Aalet al., respectively, for patients who had tumor size more
than 5cm [11, 12].
In our study, 12.2% of patients had lymph node
involvement at time of diagnosis. This result is similar to
Shouman et al.[10]andtheIRSIV[11]whofoundthat15%
of patients had LN involvement. Hosoi et al. [14] showed
that 19% of patients had LN involvement. Our study showed
that 43.9% of patients had metastasis at time of diagnosis.
Koscielniak et al. [15] reported that fewer than 25% of
patients have metastatic disease at diagnosis. Also, 63% of
patients received radiotherapy, this result is the same result
reported by Shouman et al. [10].
In our study, according to IRS postsurgical grouping
classiﬁcation, group 4 was the most frequent group (43.9%),
followed by group 1 (26.8%), then group 3 (19.5%), and
lastly group 2 (9.8%). These results are diﬀerent from
Hessissen et al. [13] who reported that group 3 was the most
frequentgroup(51%)thengroup2,1,and4(22%,14%,and
13% of patients, resp.). Shouman et al. [10] and Hosoi et al.
[14] reported the same order of frequency as Hessissen et al.
Regarding the IRS presurgical staging classiﬁcation, stage
IV was the most frequent stage (43.9%) of our patients,6 ISRN Oncology
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Figure 5: OS according to IRS presurgical stages of patients. The
estimated OSrate was 75% ± 21, 80.2% ± 12.8, and 22.2% ± 10.8
f o rp a t i e n t sw i t hs t a g eI I ,s t a g eI I I ,a n ds t a g eI V ,r e s p e c t i v e l y .
followed by stage III (29.3%), then stage I (17.1%), and lastly
stage II (9.7%). These results diﬀer from Shouman et al.
[10] who reported that stage III was the most frequent stage
(46%), followed by stage IV (24%), then stage I (19%), and
lastlystageII(11%).Hosoietal.[14]reportedthesameorder
of frequency as Shouman et al. while Abd El-Aal et al. [12]
founded that stage II was the most frequent stage, followed
by stage III, then stage IV, and lastly stage I.
High percentage of patients with metastasis at time of
diagnosis, group 4 and stage IV in our patients can be
explained by the unawareness of primary health care physi-
cians about early presenting symptoms and signs of the dis-
ease, together with the unavailability of diagnostic facilities
which can allow earlier picking up of cases with localized
disease.
In our study, there was a signiﬁcant statistical relation-
ship between histopathologic subtypes of tumor and metas-
tasis, all patients with alveolar subtype had metastasis at time
of diagnosis while only 31% of embryonal subtype had me-
tastasis.
In our study, there was no signiﬁcant relationship be-
tween primary site of tumor and age (P = 0.4). Wiener [5]
statedthatheadandneckRMSaremorecommoninyounger
children; on the other hand, extremities RMS are more com-
monly found in adolescents.
Our results showed that there was highly signiﬁcant
(P<0.001) relationship between primary site of tumor and
histopathologic subtype. All patients with head and neck
RMS and 50% of both genitourinary and retroperitoneum
RMS were of embryonal subtype, while 58.3% of extremities
RMS were of alveolar subtype. Wiener [5] found that
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Figure 6:OSaccordingtoprotocolsoftreatment.TheestimatedOS
rate was 48.9% ± 9.6 and 76.9% ± 15.3 for patients on VAC and
CWS protocol, respectively. While mean OS time was 42.6 months
±5.9 and 22 months ±1.7 for patients on VAC and CWS protocol,
respectively.
head and neck RMS are being characterized by embryonal
histology in most cases; on the other hand, extremities
RMS are more likely to have an alveolar subtype and nearly
80% of genitourinary tract RMS are embryonal in nature.
Lawrence et al. [16] reported that head and neck RMS are
most commonly of the embryonal subtype. Mandell et al.
[17] reported that nearly 50% of extremities RMS are of the
alveolar subtype.
In our study, there was a signiﬁcant relationship (P =
0.02) between age and outcome of patients. Seventy ﬁve
percent of patients more than 10 years died while about
70% of patients less than 10 years survived. Our results
are in agreement with Punyko et al. [7] who found that
patients aged 1–9 years at time of diagnosis showed good
prognosis, while those below 1 year and 10–19 years showed
poor prognosis. On the other hand, our results revealed no
signiﬁcant statistical relationship between primary site of
tumor and outcome. These results are not matched with
Crist et al. [11] who reported that primary sites with more
favorable prognosis include the orbit and nonparameningeal
head and neck, paratestis, vulva, vagina, uterus, and biliary
tract.
In our study, there was no signiﬁcant relationship be-
tween histopathologic subtype of tumor and outcome (P>
0.05). The IRS-IV did not include histology as an inde-
pendent prognostic factor. There is evidence to suggest that
site, which is associated with histopathologic subtype, is
an independent prognostic factor, and that histology is a
prognostic factor only because of its association with site
[18].ISRN Oncology 7
Our study reported that there was a signiﬁcant relation-
ship (P = 0.0013) between metastasis and outcome, where
66.7% of patients who had metastasis at time of diagnosis
died while 82.6% of patients without metastasis survived.
Breneman et al. [19] found that children with metastatic
disease at diagnosis have the poorest prognosis and the
prognostic signiﬁcance of metastatic disease is modiﬁed by
tumor histology (embryonal is more favorable than alveolar)
and by the number of metastatic sites.
In our study, 5-year OS was 56.9%. This result is quite
near to the 50% 5-year OS reported by Shouman et al. [10]
but lower than the 74% reported by Abd El-Aal et al. [12].
Hessissen et al. [13] reported 10 years OS of 70%. Hosoi et
al. [14] reported 69% 3-year OS and 61% 5-year OS.
In our study, 5-year FFS was 68.3%. This result is similar
to that reported by Abd El-Aalet al. (68%) [12]b u th i g h e r
than the 40% 5-year FFS reported by Shouman et al. [10].
I no u rs t u d y ,t h ee s t i m a t e dO Si nr e l a t i o nt oa g ew a s
higher in patients < 10 years than in patients ≥10 years
(66.3% versus 25%). Abd El-Aal et al. [12] reported that OS
was56%and46%forpatient<10and ≥10yearsold,respec-
tively.
Our results showed that the estimated OS in rela-
tion to histopathologic subtypes was higher in embryonal
subtype than in alveolar subtype (53.9% versus 41.7%).
Abd El-Aal et al. [12] reported that 5-year OS was 80% and
65% for embryonal and alveolar subtype, respectively, while
Pappo et al. [4] reported that 5-year OS was 64% and 26%
for embryonal and alveolar subtype, respectively.
In relation to the IRS presurgical staging classiﬁcation,
our results showed that the highest estimated OS was stage
I (100%) followed by stage III (80.2%), then stage II (75%),
and lastly stage IV with (22.2%). Hosoi et al. [14]. found that
the estimated OS was highest in stage I followed by stage II
then stage III and lastly stage IV with 79%, 77%, 59%, and
36% for stage I, II, III, and IV, respectively.
Since 2008, CWS 2002 protocol was selected for treat-
ment of soft tissue sarcomas in our unit. Our study showed
that there was a signiﬁcant statistical relationship (P = 0.03)
between protocol of treatment and outcome, where 84.6%
of patients who received CWS survived versus 50% of those
who received VAC protocol. The estimated OS was higher in
patientswhoreceivedCWSprotocolthanthosewhoreceived
VAC protocol (76.9 versus 48.9%). Also, the estimated FFS
was higher for patients who received CWS protocol than
those who received VAC protocol with 76.9% and 63.4% for
CWS and VAC protocols, respectively.
5. Conclusion
Apart from the higher prevalence of stage IV and group 4
in our patients and the higher percentage of patients with
primary tumor site in the extremities, the epidemiological
characteristicsofourpatientsarequiteneartotheworldwide
data. The application of the intensive-risk-based CWS2002
protocol for treating our patients had led to improvement in
the curability of the disease.
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